Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing

Pryor, Kimberley Jane; Goddard, Jessica; Goldstein, David; Stricker, Phillip D.; Russell, Pamela J.; Golovsky, David; Penny, Ronald

doi:10.1038/bjc.1995.155

Cited by 59 publications

(48 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the data from this study, phenotypic and functional characteristics of CD2+ cells from patients with SBTCC are associated with different clinical responses to the prophylactic intracavitary BCG treatment. These results agree with previous findings in animal models that confirm the pivotal role of T lymphocytes and NK cells in BCG-mediated anti-tumour activity (Carballido et al, 1990b;Pryor et al, 1995;Thanhauser et al, 1995;Turner and Dockrell, 1996).…”

Section: Discussionsupporting

confidence: 83%

“…These effects are observed at 3 and 6 months after the initiation of the six weekly instillations of BCG. The existence of these systemic modulatory effects of the intracavitary instillations with BCG agree with previous observations of functional effects of cytokine production by peripheral blood monocytes associated with this treatment (Jackson et al, 1995;Pryor et al, 1995). These systemic effects uphold the claim of functional lymphocyte interactions between peripheral blood lymphocytes and those involved in the local inflammatory bladder wall response (Prescott et al, 1992;Erton et al, 1996).…”

Section: Discussionsupporting

confidence: 78%

“…Infiltration of activated CD4+ and CD8+ T lymphocytes and macrophages in the bladder wall appears to be related to the therapeutic activity of BCG (Pryor et al, 1995). The immune system is a complex cellular and molecular net with multiple and continuous functional interaction among its elements.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients

et al. 1999

View full text Add to dashboard Cite

SummaryWe investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guérin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA-DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionsupporting

confidence: 78%

See 1 more Smart Citation

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients

et al. 1999

View full text Add to dashboard Cite

show abstract

“…This therapy has been demonstrated to be more effective than localized chemotherapy and radiotherapy. Although the exact mechanisms through which BCG mediates antitumour immunity remain elusive, an induction of localized cellular immune responses reflecting activation of various immune cells has been proposed [3][4][5][6][7]. Several lines of evidence suggest that macrophages actively mediate BCG's anti-bladder cancer activity.…”

Section: Introductionc Ei_4105 359368mentioning

confidence: 99%

Interleukin-10 inhibitsMycobacterium bovisbacillus Calmette–Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells

Luo

Han²,

Evanoff

et al. 2010

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe mechanisms underlying bacillus Calmette-Guérin (BCG) immunotherapy of bladder cancer currently remain elusive. Previously, we demonstrated that macrophages were cytotoxic to bladder cancer cells upon BCG stimulation in vitro. However, macrophages from C57BL/6 mice were less potent than those from C3H/HeN mice for the killing of bladder cancer cells. This study was to determine whether interleukin (IL)-10 produced by macrophages in response to BCG is a causative factor for the reduced cytotoxicity in BCG-stimulated C57BL/6 macrophages. Thioglycollate-elicited peritoneal macrophages were prepared and analysed for the BCG induction of cytotoxicity, cytokines and nitric oxide (

show abstract

“…BCG has been shown to have antiproliferative effects on human bladder cancer cells in vitro in the absence of any immune effector cells (Pryor et al, 1995a(Pryor et al, , 1995b. Similar antiproliferative effects of both heat-killed and viable BCG on a panel of human bladder transitional cell carcinoma cell lines have also been described (Jackson et al, 1994).…”

Section: Induction Of Apoptosis By MCCmentioning

confidence: 73%

Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells

et al. 1998

View full text Add to dashboard Cite

Intact mycobacteria and mycobacterial cell wall extracts have been shown to inhibit the growth of human and murine bladder cancer. Their mechanism of action is, however, poorly understood. Mycobacterium phlei mycobacterial cell complex (MCC) is a cell wall preparation that has mycobacterial DNA in the form of short oligonucleotides complexed on the cell wall surface. In this study, we have investigated the possibility that MCC has anti-cancer activity that is mediated by two different mechanisms – a direct effect on cancer cell proliferation and viability and an indirect effect mediated by the production of interleukin 12 (IL-12), a cytokine known to possess anti-cancer activity. We have found that, although MCC is a potent inducer of IL-12 and IL-6 synthesis in monocytes and macrophages either in vitro or in vivo, it is unable to induce the synthesis of either IL-12, IL-6 or granulocyte–macrophage colony-stimulating factor (GM-CSF) by the human transitional bladder cancer cell lines HT-1197 and HT-1376. MCC is not directly cytotoxic towards these cancer cells, but induces apoptosis as determined by nuclear DNA fragmentation and by the release of nuclear mitotic apparatus protein. Mycobacterium phlei DNA associated with MCC is responsible for the induction of apoptosis. Our results indicate that MCC directly effects bladder cancer cells by inhibiting cellular proliferation through the induction of apoptosis, and has the potential for an indirect anti-cancer activity by stimulating cancer-infiltrating monocytes/macrophages to synthesize IL-12. © 1999 Cancer Research Campaign

show abstract

Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing

Cited by 59 publications

References 27 publications

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients

Interleukin-10 inhibitsMycobacterium bovisbacillus Calmette–Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells

Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells

Contact Info

Product

Resources

About